Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Galenica AG ( (CH:GALE) ) has provided an announcement.
Galenica AG reported a 5.0% increase in sales to CHF 1,995.4 million for the first half of 2025, with adjusted EBIT rising by 10.9% to CHF 109.9 million. The company has raised its EBIT growth outlook to between 7% and 9%, driven by strong demand for prescription drugs and positive special effects. This performance positions Galenica slightly ahead of the broader pharmaceutical and consumer healthcare markets, indicating a robust operational footing and promising future prospects.
The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF89.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.
More about Galenica AG
Galenica AG is a Swiss company engaged in the healthcare industry, focusing on pharmacies, pharmaceutical logistics, and home care services. It is listed on the Swiss stock exchange and employs approximately 8,000 people, aiming to meet the needs of customers and patients in the Swiss healthcare market.
Average Trading Volume: 85,960
Technical Sentiment Signal: Buy
Current Market Cap: CHF4.27B
For an in-depth examination of GALE stock, go to TipRanks’ Overview page.